L&P Client Horizon Therapeutics Prevails in Federal Circuit Appeal Preserving IPR Victories
The U.S. Court of Appeals for the Federal Circuit today issued a judgment summarily affirming the final written decisions of the PTAB in IPR2015-01117 and IPR2016-00283 that U.S. Patent No. 8,642,012 is not unpatentable. The IPR petitions were filed by Par Pharmaceutical, Inc. and Lupin Pharmaceuticals, Inc., respectively. The ’012 patent is owned by L&P Client Horizon Therapeutics, LLC and directed at its Ravicti®drug. L&P lawyer Matt Phillips assisted with the IPRs and the appeal.